|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 148.75 USD | +1.77% |
|
-0.74% | -14.53% |
| 12/02 | Insmed Insider Sold Shares Worth $1,979,764, According to a Recent SEC Filing | MT |
| 28/01 | Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INSMED INCORPORATED | Bio Therapeutic Drugs | +1.77% | -0.74% | -14.53% | +89.08% | +256.03% | 3.12TCr |  |  |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- INSM Stock
- Charts Insmed Incorporated
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition